Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This document updates previous Faculty of Sexual & Reproductive Healthcare (FSRH) guidance and aims to summarise the available evidence on emergency contraception (EC). The guidance is intended for use by health professionals providing EC. This document was updated in December 2020.
This document is up-to-date
Evidence from new study supports the existing FSRH recommendation that commencement of hormonal contraception should be delayed for 5 days after UPA-EC. Published 28/8/2018.
This document is up-to-date
The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1
This document is up-to-date
“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.
This document is up-to-date
This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).
This document is up-to-date
